The Latest
This Week in HIV Research: Welcome to the Real World
May 27, 2021: Recycling tenofovir in a second-line regimen; real-life two-drug regimen failure rates; jump-starting ART at sexual health clinics; viability of wearable devices in sleep assessment.
Long-Acting ART Rollout: 3 Considerations for Clinicians
Four months after the approval of cabotegravir/rilpivirine, medical providers still face some tough questions about who might best benefit and how the medication might be covered.
This Week in HIV Research: Getting Wiser About Getting Older
May 6, 2021: Epigenetic aging and HIV treatment initiation; effects of ART on cognitive decline; dearth of osteoporosis screenings for PLWH; physical therapy vs. opioids for bone/muscle pain.
What's New in U.S. HIV Clinical Treatment Guidelines
The latest update to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV occurred within the pediatric HIV prevention guidelines on April 8.
This Week in HIV Research: Redefining Failure
April 29, 2021: Measuring HIV drug susceptibility amidst extensive resistance; the reversibility of virologic failure; mobile HIV care in urban settings; whether to prescribe long-acting antiretroviral therapy.
Traditional Healers Offer a Culturally Competent Approach to HIV Testing Gaps
In sub-Saharan Africa, herbalists and spiritual healers are working closely with researchers to help reduce HIV transmission in rural communities.
CROI 2021 Highlights: New HIV Research With Clinical Impact
Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.
Clinical Trial Data Needs to Reflect the Demographics of HIV, Say Activists
A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.
HIV Data Bites: Recent Advances in Broadly Neutralizing Antibodies for HIV Prevention
While findings from the high-profile AMP studies have excited scientists, they’re only one of a wide range of bNAb avenues currently being pursued.
Long-Acting ART Is Here. How Do We Make It Work for Our Patients?
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.